Conference Coverage

This 2026 SCAI session highlighted the most influential trial data across coronary and structural heart disease from 2025.

Dr Ibrahim Mortada shares insights on his study, "Association of Tirzepatide Use with Clinical Outcomes After TAVR in Obese Patients: A Propensity-Matched Real-World Study," presented at the 2026 SCAI Scientific Sessions.

Dr Alison Ranum shares insights on her study, "Magnetic Resonance Imaging Versus Computed Tomography Angiography for Transcatheter Aortic Valve Replacement Planning: A Single-Center Experience," presented at the 2026 American College of...

Dr Adam Greenbaum shares insights on his late-breaking trial presented at the 2026 American College of Cardiology (ACC) Conference.

Dr David Rizik shares his insights on the most impactful TAVR data presented at the 2026 American College of Cardiology (ACC) Conference.

At his CRT 2026 session, Matthew Beckwith of the FDA outlined updated guidance on real-world evidence and introduced Predetermined Change Control Plans for artificial intelligence AI-enabled medical devices.

At his CRT 2026 Keynote Lecture, Dr James L. Cox emphasized the importance of treating atrial fibrillation during cardiac surgery, underscoring that failure to do so significantly worsens long-term outcomes.

Dr Apurva Patel discusses insights from the study, “Tailored Solutions for Structural Valve Degeneration: Valve-in-Valve-in-Valve TAVR With Coronary Leaflet Modification and Balloon Valve Fracture,” presented at the 2026 ACC Scientific...

Dr Saad Ur Rahman discusses findings from “National Trends in Aortic Stenosis Mortality in the Pre- and Post-TAVR Eras in the United States 1999–2023,” presented at the 2026 ACC Scientific Sessions.

Dr Devi Nair's session at CRT 2026 reviewed the rapidly evolving landscape of next-generation left atrial appendage closure devices for stroke prevention in atrial fibrillation, emphasizing iterative improvements in plug and plication...